Danaher Corporation vs Under Armour Inc Class A — how do they compare? Danaher Corporation trades at $206.85 (market cap $145.83B), while Under Armour Inc Class A trades at $5.26 (market cap $2.26B). The key difference: Danaher Corporation is far larger — about 64.5× Under Armour Inc Class A's market cap, and Danaher Corporation pays a 0.77% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| DHR | UAA | |
|---|---|---|
Market Cap | $145.83B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $8.14 |
52-Week Low | $161.91 | $4.17 |
Enterprise Value | $168.04B | $3.24B |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Under Armour (UAA) is trading at $5.265, down 10.15% with bearish technical signals despite recent earnings beats. The company faces significant fundamental challenges with negative net income margins (-9.99%) and declining revenue trends from $5.7B in 2024 to $5.2B in 2025. Recent Q1 2027 earnings showed a profit beat but weaker revenue and cautious guidance, reflecting ongoing struggles in North American and Asia-Pacific markets. Cash flow remains negative at -$362M for 2025, though valuation ratios like P/S of 0.46 appear attractive relative to peers.
The outlook remains challenging with persistent revenue declines and profitability issues offset by potential value opportunities. Key risks include weak consumer spending, inventory management challenges, and competitive pressures. Analyst consensus is mixed with 27% buy ratings but a $6.67 price target suggesting 27% upside from current levels, though institutional sentiment appears cautious given the technical bearish signals and fundamental headwinds.
Trailing returns across standard periods
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →